Phase II Trial Of Perifosine In Locally Advanced, Unresectable Or Metastatic Pancreatic Adenocarcinoma
- Determine the activity of perifosine, in terms of objective response, in patients with
locally advanced, unresectable, or metastatic pancreatic cancer.
- Determine the response duration, progression-free survival, and overall survival of
patients treated with this drug.
- Determine the toxicity of this drug in these patients.
OUTLINE: This is a multicenter study.
Patients receive oral perifosine every 6 hours for a total of 6 doses and then once daily in
the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 3 years.
PROJECTED ACCRUAL: A total of 35-84 patients will be accrued for this study within 21
Masking: Open Label, Primary Purpose: Treatment
Robert de W. Marsh, MD
University of Florida
United States: Federal Government
|Mayo Clinic Cancer Center||Rochester, Minnesota 55905|
|CCOP - Carle Cancer Center||Urbana, Illinois 61801|
|CCOP - Iowa Oncology Research Association||Des Moines, Iowa 50309-1016|
|CCOP - Metro-Minnesota||Saint Louis Park, Minnesota 55416|
|CCOP - Duluth||Duluth, Minnesota 55805|
|CCOP - Merit Care Hospital||Fargo, North Dakota 58122|
|CCOP - Northern Indiana CR Consortium||South Bend, Indiana 46601|
|CCOP - Scott and White Hospital||Temple, Texas 76508|
|Tufts - New England Medical Center||Boston, Massachusetts 02111|
|MBCCOP-Our Lady of Mercy Cancer Center||Bronx, New York 10466|